Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 162


DNA Hypomethylating Drugs in Cancer Therapy.

Sato T, Issa JJ, Kropf P.

Cold Spring Harb Perspect Med. 2017 Feb 3. pii: a026948. doi: 10.1101/cshperspect.a026948. [Epub ahead of print]


Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium.

Toth R, Scherer D, Kelemen LE, Risch A, Hazra A, Balavarca Y, Issa JJ, Moreno V, Eeles RA, Ogino S, Wu X, Ye Y, Hung RJ, Goode EL, Ulrich CM.

Cancer Epidemiol Biomarkers Prev. 2017 Jan 23. pii: cebp.0728.2016. doi: 10.1158/1055-9965.EPI-16-0728. [Epub ahead of print]


Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.

Mol Cancer Ther. 2017 Feb;16(2):397-407. doi: 10.1158/1535-7163.MCT-16-0588.


Transcriptional Selectivity of Epigenetic Therapy in Cancer.

Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ.

Cancer Res. 2017 Jan 15;77(2):470-481. doi: 10.1158/0008-5472.CAN-16-0834.


Targeting the cancer epigenome for therapy.

Jones PA, Issa JP, Baylin S.

Nat Rev Genet. 2016 Sep 15;17(10):630-41. doi: 10.1038/nrg.2016.93. Review.


Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP.

Cancer Res. 2016 Mar 15;76(6):1494-505. doi: 10.1158/0008-5472.CAN-14-2391.


Zebrafish embryos as a screen for DNA methylation modifications after compound exposure.

Bouwmeester MC, Ruiter S, Lommelaars T, Sippel J, Hodemaekers HM, van den Brandhof EJ, Pennings JL, Kamstra JH, Jelinek J, Issa JP, Legler J, van der Ven LT.

Toxicol Appl Pharmacol. 2016 Jan 15;291:84-96. doi: 10.1016/j.taap.2015.12.012.


Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP.

J Natl Cancer Inst. 2015 Nov 13;108(2). pii: djv323. doi: 10.1093/jnci/djv323.


Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. No abstract available.


Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia.

Kropf P, Barnes G, Tang B, Pathak A, Issa JP.

Leuk Lymphoma. 2016;57(4):935-41. doi: 10.3109/10428194.2015.1088654.


Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L.

J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497.


Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells.

Jin C, Qin T, Barton MC, Jelinek J, Issa JP.

Epigenetics. 2015;10(11):1006-13. doi: 10.1080/15592294.2015.1091145.


Epigenetic synergy between decitabine and platinum derivatives.

Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP.

Clin Epigenetics. 2015 Sep 11;7:97. doi: 10.1186/s13148-015-0131-z.


Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.

Lancet Oncol. 2015 Sep;16(9):1099-110. doi: 10.1016/S1470-2045(15)00038-8.


Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP.

Epigenetics. 2015;10(9):872-81. doi: 10.1080/15592294.2015.1076955.


Regulation of AURKC expression by CpG island methylation in human cancer cells.

Fujii S, Srivastava V, Hegde A, Kondo Y, Shen L, Hoshino K, Gonzalez Y, Wang J, Sasai K, Ma X, Katayama H, Estecio MR, Hamilton SR, Wistuba I, Issa JP, Sen S.

Tumour Biol. 2015 Sep;36(10):8147-58. doi: 10.1007/s13277-015-3553-5.


TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.

Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Kantarjian HM, Liang S, Estecio MR, Godley LA, Issa JP.

Cancer Res. 2015 Jul 15;75(14):2833-43. doi: 10.1158/0008-5472.CAN-14-0739.


Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.

Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP.

Clin Epigenetics. 2015 Mar 17;7:29. doi: 10.1186/s13148-015-0065-5.


TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells.

Jin C, Lu Y, Jelinek J, Liang S, Estecio MR, Barton MC, Issa JP.

Nucleic Acids Res. 2014 Jun;42(11):6956-71. doi: 10.1093/nar/gku372.


Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.

Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.

Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.

Supplemental Content

Loading ...
Support Center